STATEN
ISLAND, N.Y. , Oct. 17,
2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.
(NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage
biopharmaceutical company developing a new class of antibiotics for
difficult-to-treat bacterial infections, announced today that the
Company will participate in the Spartan Capital inaugural investor
conference on November 4, 2024 at the
Pierre Hotel in New York, New
York.
This participation aligns with our commitment to engage with
industry leaders and investors. Our presentation will offer insight
into our company's growth strategy and market position.
David P. Luci, President &
CEO of the Company, commented, "We are pleased to be invited and to
present at Spartan Capital's inaugural investor conference. This
event provides an excellent platform to showcase our company and
keep the key influencers in the capital markets apprised of our
accomplishments and future plans."
The conference, organized in partnership with B2i Digital, a
leading digital marketing firm specializing in investor
communications, will feature presentations from over 30 carefully
selected companies. The event will include panel discussions,
one-on-one meetings, and networking sessions to maximize
interactions between investors and presenters.
For more information about the conference and registration
details, please visit Spartan Capital's conference page.
About Acurx Pharmaceuticals,
Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused
on developing a new class of small molecule antibiotics
for difficult-to-treat bacterial infections. The Company's approach
is to develop antibiotic candidates with a Gram-positive selective
spectrum (GPSS®) that blocks the active site of the Gram+ specific
bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA
replication and leading to Gram-positive bacterial cell death. Its
R&D pipeline includes antibiotic product candidates that target
Gram-positive bacteria, including Clostridioides difficile,
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin
resistant Enterococcus (VRE) and drug-resistant Streptococcus
pneumoniae (DRSP).To learn more about Acurx Pharmaceuticals, please
visit www.acurxpharma.com
Forward-Looking Statements
Any statements in this
press release about our future expectations, plans and prospects,
including statements regarding our strategy, future operations,
prospects, plans and objectives, and other statements containing
the words "believes," "anticipates," "plans,"
"expects," and similar
expressions, constitute forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: whether ibezapolstat will benefit from the QIDP
designation; whether ibezapolstat will advance through the clinical
trial process on a timely basis; whether the results of the
clinical trials of ibezapolstat will warrant the submission of
applications for marketing approval, and if so, whether
ibezapolstat will receive approval from the FDA or equivalent
foreign regulatory agencies where approval is sought; whether, if
ibezapolstat obtains approval, it will be successfully distributed
and marketed; and other risks and uncertainties described in the
Company's annual report filed with the Securities and Exchange
Commission on Form 10-K for the year ended December 31, 2023, and in the Company's
subsequent filings with the Securities and Exchange Commission.
Such forward- looking statements speak only as of the date of this
press release, and Acurx disclaims any intent or obligation to
update these forward-looking statements to reflect events or
circumstances after the date of such statements, except as may be
required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President &
CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original
content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-announces-participation-at-the-spartan-capital-investor-conference-to-showcase-growth-companies-and-foster-high-level-investor-engagement-302277691.html
SOURCE Acurx Pharmaceuticals, Inc.